Home/Filings/4/0000899243-22-035085
4//SEC Filing

Mitra Satyajit Kumar 4

Accession 0000899243-22-035085

CIK 0001834645other

Filed

Nov 2, 8:00 PM ET

Accepted

Nov 3, 9:53 PM ET

Size

8.6 KB

Accession

0000899243-22-035085

Insider Transaction Report

Form 4
Period: 2022-11-01
Transactions
  • Award

    Stock Option (Right to Buy)

    2022-11-01+18,64718,647 total
    Exercise: $6.10From: 2022-11-01Exp: 2026-06-12Common Stock (18,647 underlying)
  • Award

    Stock Option (Right to Buy)

    2022-11-01+31,70031,700 total
    Exercise: $8.05From: 2024-01-26Exp: 2029-01-26Common Stock (31,700 underlying)
Footnotes (2)
  • [F1]Received pursuant to the consummation of the transactions contemplated by that certain Business Combination Agreement (the "Business Combination Agreement") between Ignyte Acquisition Corp. (the former name of the Issuer), a Delaware corporation, Peak Bio Co., Ltd., a corporation organized under the laws of the Republic of Korea ("Legacy Peak Bio"), and Ignyte Korea Co., Ltd., a corporation organized under the laws of the Republic of Korea. These stock options represent Legacy Peak Bio stock options and were initially granted to the Reporting Person on June 12, 2019 and are fully vested.
  • [F2]Received pursuant to the consummation of the transactions contemplated by the Business Combination Agreement. These stock options represent Legacy Peak Bio stock options and were initially granted to the Reporting Person on January 26, 2022. The stock options become fully vested and exercisable after two years from the initial date of grant, subject to the Reporting Person's continued employment with the Issuer.

Issuer

Peak Bio, Inc.

CIK 0001834645

Entity typeother

Related Parties

1
  • filerCIK 0001951215

Filing Metadata

Form type
4
Filed
Nov 2, 8:00 PM ET
Accepted
Nov 3, 9:53 PM ET
Size
8.6 KB